Product image of MOUNJARO 15 mg (Tirzepatide) 15 mgx0.5 ml PFS supplied by GNH India

MOUNJARO 15 mg

Active Ingredient:
Tirzepatide
Form:
PFS
Brand:
MOUNJARO
Origin:
USA

MOUNJARO 15 mg (Tirzepatide PFS) 15 mgx0.5 ml

Tirzepatide, the active ingredient in MOUNJARO 15 mg, is a GIP/GLP-1 receptor agonist presented as a 15 mg/0.5 mL pre-filled syringe for subcutaneous use. It is used to improve blood sugar levels in adults and children aged 10 and older with type 2 diabetes mellitus. GNH India supplies MOUNJARO 15 mg as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

MOUNJARO 15 mg is an injectable prescription medication designed to enhance glycemic control in patients with type 2 diabetes. It works by activating both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, which helps regulate blood sugar levels.

Strength

15 mgx0.5 ml

Pack Size

4s

Storage

2-8°

Manufacturer / TM Owner

LILLY ELI & CO

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

MOUNJARO 15 mg is indicated for the treatment of type 2 diabetes mellitus. It is designed to improve glycemic control in adults and children aged 10 and older.

  • Type 2 diabetes mellitus: Improves blood sugar levels in patients with type 2 diabetes when used alongside diet and exercise.

How It Works

  • MOUNJARO 15 mg works by activating both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual action enhances insulin secretion, suppresses glucagon release, and slows gastric emptying, thereby helping to regulate blood sugar levels in patients with type 2 diabetes mellitus.

Side Effects

MOUNJARO 15 mg may cause various side effects, ranging from common to serious. It is important to be aware of these potential adverse reactions.

Common Side Effects

  • Nausea
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • Constipation
  • Indigestion
  • Stomach (abdominal) pain

Serious or Rare Side Effects

  • Pancreatitis: Severe pain in the stomach area that may radiate to the back
  • Allergic reactions: Swelling of the face, lips, tongue, or throat, problems breathing or swallowing, severe rash or itching, fainting or dizziness, and very rapid heartbeat
  • Thyroid tumors: Symptoms include a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath
  • Low blood sugar (hypoglycemia): Dizziness, sweating, confusion, headache, blurred vision, shakiness, fast heartbeat, anxiety, irritability, hunger, weakness, and feeling jittery

Precautions & Warnings

MOUNJARO 15 mg should be used with caution, and certain precautions should be observed to ensure safe and effective treatment.

  • Allergic reactions: Do not use MOUNJARO if you have a history of allergic reactions to tirzepatide or any of its ingredients
  • Thyroid cancer: Do not use MOUNJARO if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Pancreatitis: Stop using MOUNJARO and seek medical attention if you experience severe stomach pain
  • Hypoglycemia: Monitor blood sugar levels closely, especially when used with other diabetes medications
  • Dehydration: Drink plenty of fluids to reduce the risk of dehydration due to diarrhea, nausea, or vomiting
  • Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

MOUNJARO 15 mg may interact with other medications, which can affect its efficacy and safety. It is important to be aware of these potential interactions.

Major Interactions (Avoid)

  • Sulfonylureas: Increased risk of hypoglycemia
  • Insulin: Increased risk of hypoglycemia

Moderate Interactions (Monitor Closely)

  • Other diabetes medications: May require dose adjustments to avoid hypoglycemia
  • Medications that affect gastric emptying: May alter the absorption and efficacy of MOUNJARO
  • Medications metabolized by CYP enzymes: Potential for altered metabolism and efficacy

Frequently Asked Questions

MOUNJARO 15 mg is used to improve blood sugar levels in adults and children aged 10 and older with type 2 diabetes mellitus. It is an injectable prescription medication that works by activating both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors to help regulate blood sugar levels.

Tirzepatide, the active ingredient in MOUNJARO 15 mg, works by activating both the GIP and GLP-1 receptors. This dual action enhances insulin secretion, suppresses glucagon release, and slows gastric emptying, thereby helping to regulate blood sugar levels in patients with type 2 diabetes mellitus.

The dose of MOUNJARO 15 mg is determined by a healthcare provider based on the patient's individual needs and response to the medication. It is important to follow the prescribed dosage and administration instructions provided by your healthcare provider.

The safety of MOUNJARO 15 mg during pregnancy or breastfeeding has not been established. It is important to consult with a healthcare provider before using this medication if you are pregnant, planning to become pregnant, or breastfeeding.

To order MOUNJARO 15 mg from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will then provide pricing, availability, shipping, and the necessary import paperwork.

MOUNJARO 15 mg is a GIP/GLP-1 receptor agonist, which differentiates it from other diabetes medications that may only target one of these receptors. Its dual action can provide more comprehensive blood sugar control. However, the choice of medication depends on individual patient needs and should be discussed with a healthcare provider.

MOUNJARO 15 mg should be stored at 2-8°C, kept refrigerated, protected from light, and not frozen or shaken. It is important to follow the storage instructions provided to maintain the medication's efficacy and safety.

MOUNJARO 15 mg is administered as a subcutaneous injection, typically in the stomach (abdomen), thigh, or back of the upper arm. It is important to follow the administration instructions provided by your healthcare provider to ensure proper use.

The most serious risks associated with MOUNJARO 15 mg include pancreatitis, allergic reactions, thyroid tumors, and low blood sugar (hypoglycemia). It is important to be aware of these potential risks and to seek medical attention if any severe symptoms occur.

MOUNJARO 15 mg should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also not recommended for individuals with severe gastroparesis or those who are allergic to tirzepatide or any of its ingredients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tirzepatide

MOUNJARO 2.5mg

MOUNJARO 2.5mg

2.5mgx0.5ml PFS
MOUNJARO 5mg

MOUNJARO 5mg

5mgx0.5ml PFS
MOUNJARO 7.5mg

MOUNJARO 7.5mg

7.5mgx0.5 ml PFS
MOUNJARO 10 mg

MOUNJARO 10 mg

10 mgx0.5 ml PFS

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT